Position in MRK
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$9,547,421
+$1,798,099 QoQ
Shares Held
74,299
+15.3% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.54%
of 13F equity value
Holder Rank
#760
of 3,768 holders
Holding Since
Dec 2023
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MRK Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Plato Investment Management Ltd holds $101,936,919 across 10 Drug Manufacturers - General names. MRK ranks #4 (9.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
20,772 | $24,914,562 | |
| 2 | JNJ |
Johnson & Johnson
|
72,416 | $18,391,491 | |
| 3 | ABBV |
AbbVie Inc.
|
61,586 | $15,497,501 | |
| 4 | MRK |
Merck & Co., Inc.
This page
|
74,299 | $9,547,421 | |
| 5 | AMGN |
Amgen Inc
|
22,412 | $8,115,833 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
50,583 | $6,390,656 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
106,571 | $6,140,621 | |
| 8 | AZN |
Astrazeneca PLC
|
31,725 | $6,015,694 |
All Filings in MRK
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $9,547,421 | 74,299 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $7,749,322 | 64,422 | Shares | Sole | 2026-05-05 | |
| 2025-12-31 | $7,108,102 | 67,529 | Shares | Sole | 2026-02-04 | |
| 2025-09-30 | $5,711,772 | 68,054 | Shares | Sole | 2025-11-05 | |
| 2025-06-30 | $4,997,133 | 63,127 | Shares | Sole | 2025-08-05 | |
| 2025-03-31 | $5,304,097 | 59,092 | Shares | Sole | 2025-05-20 | |
| 2024-12-31 | $5,036,075 | 50,624 | Shares | Sole | 2025-02-06 | |
| 2024-09-30 | $5,748,861 | 50,624 | Shares | Sole | 2024-11-06 | |
| 2024-06-30 | $6,210,674 | 50,167 | Shares | Sole | 2024-08-09 | |
| 2023-12-31 | $721,930 | 6,622 | Shares | Sole | 2024-02-13 | |
| No filing history on record for this holder in this stock. | ||||||